Victoza® can be used in combination with diet and exercise in patients for whom
metformin is inappropriate due to contraindication or intolerance.
In a study, 746 patients with type 2 diabetes were randomized to Victoza® 1.2 mg
(n=251), Victoza® 1.8 mg (n=247), or glimepiride 8 mg (n=248) in the 52-week,
multicentre, double-blind, double-dummy, randomized, parallel, active-controlled
LEAD™ 3 trial. These patients had previously been treated with diet/exercise (n=272)
or not more than half-maximal OAD monotherapy (n=474) for at least 2 months.
At 52 weeks, patients on Victoza® 1.8 mg saw mean A1C reductions of 1.1% (p<0.05)
and those on Victoza® 1.2 mg saw a mean reduction on 0.8% (p<0.0001) versus 0.5%
for glimepiride 8 mg (all baseline 8.2%).
The secondary endpoint of mean weight change showed a 2.5 kg reduction with
Victoza® 1.8 mg (baseline 92.6 kg), a 2.1 kg reduction with Victoza® 1.2 mg
(baseline 92.1 kg), and a 1.1 kg increase in weight with glimepiride 8 mg (baseline
The percentage of patients achieving an A1C target of <7% was 51% with Victoza®
1.8 mg, 43% with Victoza® 1.2 mg, and 28% with glimepiride 8 mg.1
Latest Product Monograph
June 15, 2017
Victoza® can be used without dose adjustment in patients with hepatic insufficiency1
There is limited clinical experience in patients with mild, moderate or severe hepatic insufficiency. No dose adjustment is required for patients with hepatic insufficiency.1
January 26, 2017
Victoza® added to innoviCares program
1.5 million Canadians already use the innoviCares payment assistance card to
save on prescription medications.
All your patient needs do is to present their innoviCares card and Victoza®
prescription at their local pharmacy. The innoviCares card will automatically cover
a portion of the drug acquisition cost of their Victoza® prescription.
The LIRA-SWITCH™ trial was a phase 4, 26-week, randomized, multicentre,
parallel-group, double-blind, double-dummy, active-controlled trial studying patients
18 years or over with a BMI of 20 kg/m2 or over and A1C between 7.5% and 9.5%
who were inadequately controlled on stable sitagliptin and metformin.
At 26 weeks, patients who were inadequately controlled on sitagliptin and metformin achieved statistically significant A1C reductions on a regimen of Victoza® and metformin versus continuing sitagliptin and metformin (-1.1% for Victoza® 1.8 mg + MET + oral placebo, n=204 vs. -0.54% for sitagliptin 100 mg + MET + placebo injection, n=203; p<0.0001).5‡
In secondary endpoints, also in patients inadequately controlled on sitagliptin and metformin: Victoza® and metformin showed statistically significant weight reductions versus continuing sitagliptin and metformin (-3.3 kg for Victoza® 1.8 mg + MET + oral placebo, n=204 vs. -1.6 kg for sitagliptin 100 mg + MET + placebo injection, n=203; p<0.0001); and Victoza® and metformin showed a statistically significant proportion of patients achieved target A1C <7% versus continuing sitagliptin and metformin (50.6% for Victoza® 1.8 mg + MET + oral placebo, n=204 vs. 26.9% for sitagliptin 100 mg + MET + placebo injection, n=203; p<0.0001).5‡
‡Baseline values for Victoza® + MET/sitagliptin + MET arm:
A1C (%): 8.3/8.2; body weight (kg): 88.9/91.2.
Victoza® can be used without dose
adjustment in patients with
moderate or mild renal insufficiency1
There is no dose adjustment required in moderate renal patients (creatinine
clearance 30-59 mL/min) or mild renal patients (60-90 mL/min).
There is very limited or no clinical experience with Victoza® in patients with severe
renal insufficiency (<30 mL/min), including end-stage renal disease; use of Victoza® in
these patients is not recommended.1
This April 2016 Product Monograph update remains unchanged in the latest
June 2017 Product Monograph update.
Contraindications in patients with personal or family history of medullary thyroid carcinoma, multiple endocrine
neoplasia syndrome type 2 (MEN 2) and pregnant or breast-feeding women
A serious warning on risk of thyroid C-cell tumours including medullary thyroid carcinoma in humans
Other relevant warnings and precautions relating to risk of CV effects (increased heart rate, PR interval prolongation),
treatment of diabetic ketoacidosis, intravenous or intramuscular administration, hypoglycemia in combination with a
sulfonylurea, individual pen use, pancreatitis, recent MI, unstable angina and congestive heart failure, hepatic and renal
impairment, gastrointestinal disease, hypersensitivity
Conditions of clinical use, adverse reactions, drug interactions and dosing instructions
See Product Monograph for complete dosing and administration. The Product Monograph is also available by calling us at 1-800-465-4334.
Ask Med Info
If you have a specific question
about Victoza®, please email our
Medical Information team using the
form below. We will get back to you
as soon as possible.
The latest Victoza® Product
Monograph dated June 15, 20171.